Connect
← Return to Tymlos Side effects
Discussion
Osteoporosis & Bone Health | Last Active: 2 hours ago | Replies (74)
Comment receiving replies
@wilweten Taken from online research: During drug testing, Tymlos (abaloparatide) caused a dose-dependent increase in a rare type of bone cancer called osteosarcoma in both male and female rats at exposures 4 to 28 times human levels. "It remains unknown if this risk applies to humans"
Replies to "@wilweten Taken from online research: During drug testing, Tymlos (abaloparatide) caused a dose-dependent increase in a..."
Connect
@willowmena
You may like to read this article: https://www.biospace.com/radius-announces-update-on-tymlos-abaloparatide-label published 23 December 2023: it starts with
"Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label.
FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021
The boxed warning had referred to the potential risk of osteosarcoma
Action follows review of long-term post-marketing data for TYMLOS and PTH class of drugs."